Dr. Ivan R. Batlle, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,207
Licensed in Texas since 2008, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: Tulane University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
KS license 04-31680 · LA license MD.08085R · MO license 2005041174 · MS license 16323 · TX license M9839 (first issued 2008; cancelled by request) -
Retina Specialist (Ophthalmology) Physician
KS license 0431680 · LA license MD.08085R · MO license 2005041174 · MS license 16323 · TX license M9839 (first issued 2008; cancelled by request)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Retina Associates LLC (12 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,207
- Services billed
- 20,908
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 8,160 | 29 |
| Imaging of retina | 1,917 | 733 |
| Injection, aflibercept, 1 mg | 1,372 | 151 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,275 | 791 |
| Injection of drug into eye | 1,249 | 346 |
| Photography of the retina | 841 | 686 |
| Injection, ranibizumab, 0.1 mg | 698 | 30 |
| Unclassified biologics | 397 | 100 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 336 | 17 |
| New patient office or other outpatient visit, 45-59 minutes | 272 | 272 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Lenexa, KS | 114 |
| Timolol Maleate Other prescribers in Lenexa, KS | 65 |
| Ketorolac Tromethamine Other prescribers in Lenexa, KS | 36 |
| Brimonidine Tartrate Other prescribers in Lenexa, KS | 32 |
| Latanoprost Other prescribers in Lenexa, KS | 27 |
| Diclofenac Sodium Other prescribers in Lenexa, KS | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 25 payments worth $1,024 in total to this clinician.
| Ani Pharmaceuticals, Inc. | $293 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $227 |
| AbbVie Inc. | $222 |
| Apellis Pharmaceuticals, Inc. | $213 |
| Genentech USA, Inc. | $48.64 |
| Harrow Eye, LLC | $20.79 |
| Food and Beverage | $1,024 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $233,996 in research payments for these studies, mostly to the institutions running them.
- Port Delivery System of Ranibizumab Extension Study
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Novartis Pharmaceuticals Corporation - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - A phase iii multicenter observation comparator study of the efficacy safety and pharmacokinetics
Genentech, Inc. - Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degener…
AbbVie Inc. - Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie Inc. · Recruiting · NCT07007065
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.